Novo Nordisk to Initiate Phase 3 Development of Semaglutide

by Eddie Staley, Benzinga Editor
June 21, 2012 4:14 PM | 9 seconds read | Make a Comment
Loading...
Loading...
Novo Nordisk
NVO
today announced the decision to initiate the global phase 3 development programme for semaglutide, a once-weekly human GLP-1 (Glucagon-Like Peptide-1) analogue.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!